Literature DB >> 20444895

Ebola virus glycoprotein counteracts BST-2/Tetherin restriction in a sequence-independent manner that does not require tetherin surface removal.

Lisa A Lopez1, Su Jung Yang, Heiko Hauser, Colin M Exline, Kevin G Haworth, Jill Oldenburg, Paula M Cannon.   

Abstract

BST-2/tetherin is an interferon-inducible protein that restricts the release of enveloped viruses from the surface of infected cells by physically linking viral and cellular membranes. It is present at both the cell surface and in a perinuclear region, and viral anti-tetherin factors including HIV-1 Vpu and HIV-2 Env have been shown to decrease the cell surface population. To map the domains of human tetherin necessary for both virus restriction and sensitivity to viral anti-tetherin factors, we constructed a series of tetherin derivatives and assayed their activity. We found that the cytoplasmic tail (CT) and transmembrane (TM) domains of tetherin alone produced its characteristic cellular distribution, while the ectodomain of the protein, which includes a glycosylphosphatidylinositol (GPI) anchor, was sufficient to restrict virus release when presented by the CT/TM regions of a different type II membrane protein. To counteract tetherin restriction and remove it from the cell surface, HIV-1 Vpu required the specific sequence present in the TM domain of human tetherin. In contrast, the HIV-2 Env required only the ectodomain of the protein and was sensitive to a point mutation in this region. Strikingly, the anti-tetherin factor, Ebola virus GP, was able to overcome restriction conferred by both tetherin and a series of functional tetherin derivatives, including a wholly artificial tetherin molecule. Moreover, GP overcame restriction without significantly removing tetherin from the cell surface. These findings suggest that Ebola virus GP uses a novel mechanism to circumvent tetherin restriction.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20444895      PMCID: PMC2898217          DOI: 10.1128/JVI.02636-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  45 in total

1.  Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism.

Authors:  Janet L Douglas; Kasinath Viswanathan; Matthew N McCarroll; Jean K Gustin; Klaus Früh; Ashlee V Moses
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

2.  HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor.

Authors:  Christine Goffinet; Ina Allespach; Stefanie Homann; Hanna-Mari Tervo; Anja Habermann; Daniel Rupp; Lena Oberbremer; Christian Kern; Nadine Tibroni; Sonja Welsch; Jacomine Krijnse-Locker; George Banting; Hans-Georg Kräusslich; Oliver T Fackler; Oliver T Keppler
Journal:  Cell Host Microbe       Date:  2009-03-19       Impact factor: 21.023

3.  HM1.24 is internalized from lipid rafts by clathrin-mediated endocytosis through interaction with alpha-adaptin.

Authors:  Naoko Masuyama; Toshio Kuronita; Rika Tanaka; Tomonori Muto; Yuko Hirota; Azusa Takigawa; Hideaki Fujita; Yoshinori Aso; Jun Amano; Yoshitaka Tanaka
Journal:  J Biol Chem       Date:  2009-04-08       Impact factor: 5.157

4.  The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu.

Authors:  Liwei Rong; Jianyong Zhang; Jennifer Lu; Qinghua Pan; René-Pierre Lorgeoux; Claudette Aloysius; Fei Guo; Shan-Lu Liu; Mark A Wainberg; Chen Liang
Journal:  J Virol       Date:  2009-05-27       Impact factor: 5.103

5.  Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion.

Authors:  Eri Miyagi; Amy J Andrew; Sandra Kao; Klaus Strebel
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-05       Impact factor: 11.205

6.  Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2.

Authors:  Bin Jia; Ruth Serra-Moreno; William Neidermyer; Andrew Rahmberg; John Mackey; Ismael Ben Fofana; Welkin E Johnson; Susan Westmoreland; David T Evans
Journal:  PLoS Pathog       Date:  2009-05-15       Impact factor: 6.823

7.  HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation.

Authors:  Bastien Mangeat; Gustavo Gers-Huber; Martin Lehmann; Madeleine Zufferey; Jeremy Luban; Vincent Piguet
Journal:  PLoS Pathog       Date:  2009-09-04       Impact factor: 6.823

8.  Nef proteins from simian immunodeficiency viruses are tetherin antagonists.

Authors:  Fengwen Zhang; Sam J Wilson; Wilmina C Landford; Beatriz Virgen; Devon Gregory; Marc C Johnson; Jan Munch; Frank Kirchhoff; Paul D Bieniasz; Theodora Hatziioannou
Journal:  Cell Host Microbe       Date:  2009-06-04       Impact factor: 21.023

9.  Vpu antagonizes BST-2-mediated restriction of HIV-1 release via beta-TrCP and endo-lysosomal trafficking.

Authors:  Richard S Mitchell; Chris Katsura; Mark A Skasko; Katie Fitzpatrick; David Lau; Autumn Ruiz; Edward B Stephens; Florence Margottin-Goguet; Richard Benarous; John C Guatelli
Journal:  PLoS Pathog       Date:  2009-05-29       Impact factor: 6.823

10.  Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion.

Authors:  Ravindra K Gupta; Stéphane Hué; Torsten Schaller; Ernst Verschoor; Deenan Pillay; Greg J Towers
Journal:  PLoS Pathog       Date:  2009-05-22       Impact factor: 6.823

View more
  74 in total

1.  BST-2 diminishes HIV-1 infectivity.

Authors:  Jianyong Zhang; Chen Liang
Journal:  J Virol       Date:  2010-09-22       Impact factor: 5.103

2.  Role of the endocytic pathway in the counteraction of BST-2 by human lentiviral pathogens.

Authors:  David Lau; Wilson Kwan; John Guatelli
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

3.  Novel Arenavirus Entry Inhibitors Discovered by Using a Minigenome Rescue System for High-Throughput Drug Screening.

Authors:  Jessica Y Rathbun; Magali E Droniou; Robert Damoiseaux; Kevin G Haworth; Jill E Henley; Colin M Exline; Hyeryun Choe; Paula M Cannon
Journal:  J Virol       Date:  2015-06-03       Impact factor: 5.103

4.  Gag induces the coalescence of clustered lipid rafts and tetraspanin-enriched microdomains at HIV-1 assembly sites on the plasma membrane.

Authors:  Ian B Hogue; Jonathan R Grover; Ferri Soheilian; Kunio Nagashima; Akira Ono
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

Review 5.  Innate immune evasion by filoviruses.

Authors:  Christopher F Basler
Journal:  Virology       Date:  2015-04-03       Impact factor: 3.616

Review 6.  The restriction factors of human immunodeficiency virus.

Authors:  Reuben S Harris; Judd F Hultquist; David T Evans
Journal:  J Biol Chem       Date:  2012-10-05       Impact factor: 5.157

7.  BST-2/tetherin-mediated restriction of chikungunya (CHIKV) VLP budding is counteracted by CHIKV non-structural protein 1 (nsP1).

Authors:  Philip H Jones; Martina Maric; Marisa N Madison; Wendy Maury; Richard J Roller; Chioma M Okeoma
Journal:  Virology       Date:  2013-02-12       Impact factor: 3.616

8.  Ebola Virus Glycoprotein Promotes Enhanced Viral Egress by Preventing Ebola VP40 From Associating With the Host Restriction Factor BST2/Tetherin.

Authors:  Jean K Gustin; Ying Bai; Ashlee V Moses; Janet L Douglas
Journal:  J Infect Dis       Date:  2015-03-27       Impact factor: 5.226

9.  HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment.

Authors:  Heiko Hauser; Lisa A Lopez; Su Jung Yang; Jill E Oldenburg; Colin M Exline; John C Guatelli; Paula M Cannon
Journal:  Retrovirology       Date:  2010-06-07       Impact factor: 4.602

Review 10.  Post-exposure treatments for Ebola and Marburg virus infections.

Authors:  Robert W Cross; Chad E Mire; Heinz Feldmann; Thomas W Geisbert
Journal:  Nat Rev Drug Discov       Date:  2018-01-29       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.